<?xml version='1.0' encoding='utf-8'?>
<document id="30335192"><sentence text="Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example." /><sentence text="GDC-0810 was under development as an oral anti-cancer drug for the treatment of estrogen receptor-positive breast cancer as a single agent or in combination"><entity charOffset="80-88" id="DDI-PubMed.30335192.s2.e0" text="estrogen" /></sentence><sentence text=" In vitro data indicated that GDC-0810 is a potent inhibitor of OATP1B1/1B3" /><sentence text=" To assess clinical risk, a PBPK model was developed to predict the transporter drug-drug interaction (tDDI) between GDC-0810 and pravastatin in human"><entity charOffset="130-141" id="DDI-PubMed.30335192.s4.e0" text="pravastatin" /></sentence><sentence text=" The PBPK model was constructed in SimcypÂ® by integrating in vitro and in vivo data for GDC-0810" /><sentence text=" The prediction of human pharmacokinetics (PK) was verified using GDC-0810 phase I clinical PK data" /><sentence text=" The Simcyp transporter DDI model was verified using known OATP1B1/1B3 inhibitors (rifampicin, cyclosporine and gemfibrozil) and substrate (pravastatin), prior to using the model to predict GDC-0810 tDDI"><entity charOffset="83-93" id="DDI-PubMed.30335192.s7.e0" text="rifampicin" /><entity charOffset="95-107" id="DDI-PubMed.30335192.s7.e1" text="cyclosporine" /><entity charOffset="112-123" id="DDI-PubMed.30335192.s7.e2" text="gemfibrozil" /><entity charOffset="140-151" id="DDI-PubMed.30335192.s7.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e0" e2="DDI-PubMed.30335192.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e0" e2="DDI-PubMed.30335192.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e0" e2="DDI-PubMed.30335192.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e0" e2="DDI-PubMed.30335192.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e1" e2="DDI-PubMed.30335192.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e1" e2="DDI-PubMed.30335192.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e1" e2="DDI-PubMed.30335192.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e2" e2="DDI-PubMed.30335192.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30335192.s7.e2" e2="DDI-PubMed.30335192.s7.e3" /></sentence><sentence text=" The effect of GDC-0810 on pravastatin PK was then predicted based on the proposed clinical scenarios"><entity charOffset="15-23" id="DDI-PubMed.30335192.s8.e0" text="GDC-0810" /><entity charOffset="27-41" id="DDI-PubMed.30335192.s8.e1" text="pravastatin PK" /><pair ddi="false" e1="DDI-PubMed.30335192.s8.e0" e2="DDI-PubMed.30335192.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30335192.s8.e0" e2="DDI-PubMed.30335192.s8.e1" /></sentence><sentence text=" Sensitivity analysis was conducted on the parameters with uncertainty" /><sentence text=" The developed PBPK model described the PK profile of GDC-0810 reasonably well" /><sentence text=" In the tDDI verification, the model reasonably predicted pravastatin tDDI caused by rifampicin and gemfibrozil OATP1B1/3 inhibition but under-predicted tDDI caused by cyclosporine"><entity charOffset="58-69" id="DDI-PubMed.30335192.s11.e0" text="pravastatin" /><entity charOffset="85-95" id="DDI-PubMed.30335192.s11.e1" text="rifampicin" /><entity charOffset="100-111" id="DDI-PubMed.30335192.s11.e2" text="gemfibrozil" /><entity charOffset="168-180" id="DDI-PubMed.30335192.s11.e3" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e0" e2="DDI-PubMed.30335192.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e0" e2="DDI-PubMed.30335192.s11.e1" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e0" e2="DDI-PubMed.30335192.s11.e2" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e0" e2="DDI-PubMed.30335192.s11.e3" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e1" e2="DDI-PubMed.30335192.s11.e1" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e1" e2="DDI-PubMed.30335192.s11.e2" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e1" e2="DDI-PubMed.30335192.s11.e3" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e2" e2="DDI-PubMed.30335192.s11.e2" /><pair ddi="false" e1="DDI-PubMed.30335192.s11.e2" e2="DDI-PubMed.30335192.s11.e3" /></sentence><sentence text=" The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1"><entity charOffset="15-23" id="DDI-PubMed.30335192.s12.e0" text="GDC-0810" /><entity charOffset="27-41" id="DDI-PubMed.30335192.s12.e1" text="pravastatin PK" /><entity charOffset="79-90" id="DDI-PubMed.30335192.s12.e2" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.30335192.s12.e0" e2="DDI-PubMed.30335192.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30335192.s12.e0" e2="DDI-PubMed.30335192.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30335192.s12.e0" e2="DDI-PubMed.30335192.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30335192.s12.e1" e2="DDI-PubMed.30335192.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30335192.s12.e1" e2="DDI-PubMed.30335192.s12.e2" /></sentence><sentence text="01-2" /><sentence text="05 and AUC ratio 1" /><sentence text="04-2" /><sentence text="23)" /><sentence text=" The observed tDDI (Cmax ratio 1" /><sentence text="20 and AUC ratio 1" /><sentence text="41) was within the range of the predicted values" /><sentence text=" This work demonstrates an approach using a PBPK model to prospectively assess tDDI caused by a new chemical entity as an OATP1B1/3 uptake transporter inhibitor to assess clinical risk and to support development strategy" /><sentence text="" /></document>